Johnson & Johnson has rewarded shareholders with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback